var data={"title":"Hyaluronidase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hyaluronidase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6317?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">see &quot;Hyaluronidase: Drug information&quot;</a> and <a href=\"topic.htm?path=hyaluronidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hyaluronidase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179308\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amphadase;</li>\n      <li>Hylenex;</li>\n      <li>Vitrase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047693\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Extravasation</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442601\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin test:</b> Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dehydration:</b> <i>Hypodermoclysis:</i> SubQ: 15 units added to each 100 mL of replacement fluid to be administered; dosing extrapolated from experience with larger volumes (ie, in older patients, 150 units facilitates absorption of &ge;1,000 mL of solution). The volume of subcutaneous fluid administered is dependent upon the age, weight, and clinical condition of the patient, as well as laboratory determinations; maximum daily volume of clysis is 25 mL/kg/<b>day</b> and the rate of administration should not exceed 2 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation:</b> Limited data available: SubQ, intradermal: Use 5 separate 0.2 mL injections of a 15 to 150 units/mL solution into the extravasation site at the leading edge (Hurst 2004; Kuensting 2010; MacCara 1983). <b>Note:</b> Some centers determine the concentration of hyaluronidase based upon the volume of extravasation, so for smaller extravasation volumes (&lt;100 mL), a less concentrated solution (15 units/mL) has been used or by the medication risk of tissue toxicity (based on pH, osmolarity, known tissue toxicity) (MacCara 1983).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047687\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">see &quot;Hyaluronidase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin test:</b> Infants, Children, and Adolescents: Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dehydration:</b> <i>Hypodermoclysis:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ prior to infusion: SubQ: 150 units or 200 units, followed by subcutaneous isotonic fluid administration at a rate appropriate for age, weight, and clinical condition of the patient; 150 units facilitates absorption of &ge;1,000 mL of solution. If the infusion is continued greater than 24 hours, additional doses have been administered at 24 hour intervals up to a total of 3 doses (Allen 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Added to replacement solution: Dose dependent on volume to be infused; 150 units of hyaluronidase facilitates the absorption of &ge;1,000 mL of fluid; for patients (ie, young infants) who require smaller volumes for replacement fluid (&le;100 mL), 15 units added for every 100 mL of replacement fluid has been used at some centers; maximum daily dose: 150 units/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum clysis volumes:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;3 years: Volume of a single clysis should not exceed 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;3 years and Adolescents: Rate and volume of a single clysis should not exceed those used for infusion of IV fluids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dispersion/absorption enhancement of injected drugs:</b> Children and Adolescents: SubQ: 50 to 300 units (usual dose: 150 units) either injected prior to drug administration or added to injection solution (consult compatibility reference prior to mixing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation:</b> Limited data available: Infants, Children, and Adolescents: SubQ, intradermal: Use 5 separate 0.2 mL injections of a 150 units/mL solution into the extravasation site at the leading edge as soon as possible (preferably within 1 hour) after extravasation is recognized (Hurst 2004; Wiegand 2010). <b>Note:</b> Some centers may determine concentration of hyaluronidase based upon the medication risk of tissue toxicity (risk determined by pH, osmolarity, known tissue toxicity) or by volume of extravasation so for smaller volumes (&lt;100 mL), a less concentrated solution (15 units/mL) has been used (Hurst 2004; MacCara 1983; Sokol 1998; Wiegand 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urography, subcutaneous:</b> Infants, Children, and Adolescents: SubQ: 75 units over each scapula followed by injection of contrast medium at the same site; patient should be in the prone position during drug administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin test:</b> Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dehydration:</b> <i>Hypodermoclysis:</i> SubQ: 150 or 200 units followed by subcutaneous isotonic fluid administration &ge;1,000 mL <b>or </b>may be added to small volumes (&le;200 mL) of subcutaneous replacement fluid. Rate and volume of a single clysis should not exceed those used for infusion of IV fluids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dispersion/absorption enhancement of injected drugs:</b> SubQ: 50 to 300 units (usual dose: 150 units) either injected prior to drug administration or added to injection solution (consult compatibility reference prior to mixing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179291\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amphadase: 150 units/mL (1 mL) [contains edetate disodium, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hylenex: 150 units/mL (1 mL [DSC]) [contains albumin human, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hylenex: 150 units/mL (1 mL) [contains albumin human, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitrase: 200 units/mL (1.2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 units/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047697\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do not administer IV (enzyme is rapidly inactivated and desired effects will not be produced)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extravasation management: May administer undiluted (150 units/mL) or dilutions may be used for smaller volumes of extravasation. Infiltrate area of extravasation with 5 small injections at the leading edge; use 27- or 30-gauge needles and change needle between each skin entry to prevent bacterial contamination and minimize pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179304\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Amphadase, Hylenex: Store intact vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vitrase: Store intact vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. If adding to other injectable solutions, store admixture at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F) and use within 6 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047696\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct therapy to increase the dispersion and absorption of other drugs; adjunct therapy to increase rate of absorption of parenteral fluids given by hypodermoclysis for hydration; adjunct therapy in subcutaneous urography for improving resorption of radiopaque agents (all indications: FDA approved in all ages); has also been used in the management of IV extravasations </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179345\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylactic-like reactions (retrobulbar block or IV injections), anaphylaxis, hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179297\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to hyaluronidase or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179281\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Use with caution in patients with reported history of bee sting allergy; hyaluronidase is an active component in bee venom (Lee 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sensitization: Discontinue if sensitization occurs (a skin test may be performed to determine hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some products may contain albumin; albumin carries an extremely remote risk for transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD). No cases of transmission of viral diseases, CJD, or vCJD have been identified for licensed albumin or albumin contained in other licensed products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For labeled indications, do not administer intravenously (enzyme is rapidly inactivated and desired effects will not be produced); do not inject in or around infected or inflamed areas; may spread localized infection. Do not apply directly to the cornea; not for topical use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Ineffective for extravasation management of vasoconstrictors (eg, dopamine, epinephrine, norepinephrine, phenylephrine, vasopressin) or to reduce swelling of bites or stings; do not use in these settings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299453\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179286\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13355&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<b> Exceptions: </b>EPINEPHrine (Nasal); EPINEPHrine (Oral Inhalation); Isometheptene; Pseudoephedrine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Hyaluronidase may enhance the adverse/toxic effect of DOPamine.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179288\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies (not conducted with all products). Administration during labor did not cause any increase in blood loss or differences in cervical trauma. It is not known whether it affects the fetus if used during labor. Hyaluronidase has been evaluated for use prior to intracytoplasmic sperm injection (ICSI) to increase male fertility (DeVos 2008; Evison 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047692\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe appearance of lesion for induration, swelling, discoloration, blanching, and blister formation every 15 minutes for &sim;2 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179280\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Enzymatically modifies the permeability of connective tissue through hydrolysis of hyaluronic acid, one of the chief components of tissue cement which offers resistance to diffusion of liquids through tissues; hyaluronidase increases the distribution/dispersion and absorption of locally injected or extravasated substances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179296\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: SubQ: Immediate; when used for extravasation, there is usually a reduction in swelling within 15 to 30 minutes after administration (Zenk 1981b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 24 to 48 hours (variable)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5164759\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amphadase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 units/mL (1 mL): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hylenex Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 units/mL (1 mL): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vitrase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (1.2 mL): $112.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038653\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Facidase (IN);</li>\n      <li>H-lase (KR);</li>\n      <li>Hyalase (AU, BB, BH, BM, BS, BZ, CY, GR, GY, IL, JM, MT, NZ, PR, SG, SR, TR, TT, ZA);</li>\n      <li>Hyalasedessau (KR);</li>\n      <li>Hyalozima (BR);</li>\n      <li>Hyaluronidase Choay (FR);</li>\n      <li>Hyanid (BD);</li>\n      <li>Hyase (HN);</li>\n      <li>Hyason (NL);</li>\n      <li>Hyfresh (QA);</li>\n      <li>Hylase (AT, BG, CZ, DE, PL, VN);</li>\n      <li>Hylorase (IN);</li>\n      <li>Hynidase (ET, IN);</li>\n      <li>Jaluran (IT);</li>\n      <li>Lasonil (PT);</li>\n      <li>Longidaza (RU);</li>\n      <li>Lydase (RU, UA);</li>\n      <li>Lyrase (RU);</li>\n      <li>Malinda (KR);</li>\n      <li>Nydase (RU);</li>\n      <li>Penetrase (DK);</li>\n      <li>Permease (CH);</li>\n      <li>Sprase (JP);</li>\n      <li>Unidasa (AR, PY);</li>\n      <li>Vitrase (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen CH, Etzwiler LS, Miller MK, et al, &quot;Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration,&quot; <i>Pediatrics</i>, 2009, 124(5):e858-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/19805455/pubmed\" target=\"_blank\" id=\"19805455\">19805455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Vos A, Van Landuyt L, Van Ranst H, et al, &quot;Randomized Sibling-Oocyte Study Using Recombinant Human Hyaluronidase versus Bovine-Derived Sigma Hyaluronidase in ICSI Patients,&quot; <i>Hum Reprod</i>, 2008, 23(8):1815-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/18540008/pubmed\" target=\"_blank\" id=\"18540008\">18540008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evison M, Pretty C, Taylor E, et al, &quot;Human Recombinant Hyaluronidase (Cumulase) Improves Intracytoplasmic Sperm Injection Survival and Fertilization Rates,&quot; <i>Reprod Biomed Online,</i> 2009, 18(6):811-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/19490785/pubmed\" target=\"_blank\" id=\"19490785\">19490785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flemmer L and Chan JS, &quot;A Pediatric Protocol for Management of Extravasation Injuries,&quot;  <i>Pediatr Nurs</i>, 1993, 19(4):355-8, 424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/8414723/pubmed\" target=\"_blank\" id=\"8414723\">8414723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines.<i> Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuensting LL. Treatment of intravenous infiltration in a neonate. <i>J Pediatr Health Care</i>. 2010;24:184-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20417890/pubmed\" target=\"_blank\" id=\"20417890\">20417890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Grummer SE, Kriegel D, et al, &quot;Hyaluronidase,&quot; <i>Dermatol Surg</i>, 2010, 36(7):1071-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20482727/pubmed\" target=\"_blank\" id=\"20482727\">20482727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME, &ldquo;Extravasation: A Hazard of Intravenous Therapy,&rdquo; <i>Drug Intell Clin Pharm</i>, 1983, 17(10):713-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raszka WV, Keuser TK, Smith FR, et al, &ldquo;The Use of Hyaluronidase in the Treatment of Intravenous Extravasation Injuries,&rdquo; <i>J Perinatol</i>, 1990, 10(2):146-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/2358898 /pubmed\" target=\"_blank\" id=\"2358898 \">2358898 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokol DK, Dahlmann A, Dunn DW.  Hyaluronidase treatment for intravenous phenytoin extravasation. <i>Journal of child neurology</i>. 1998;13(5):246-247.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spandorfer PR, Mace SE, Okada PJ, et al, &quot;A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department,&quot; <i>Clin Ther</i>, 2012, 34(11):2232-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/23062548/pubmed\" target=\"_blank\" id=\"23062548\">23062548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiegand R, Brown J. Hyaluronidase for the management of dextrose extravasation. <i> Am J Emerg Med</i>. 2010;28(2):257.e1-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/20159411/pubmed\" target=\"_blank\" id=\"20159411\">20159411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE, Dungy CI, and Greene GR, &ldquo;Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,&rdquo; <i>Am J Dis Child</i>, 1981, 135(12):1113-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-pediatric-drug-information/abstract-text/7315807/pubmed\" target=\"_blank\" id=\"7315807\">7315807</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13355 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179308\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047693\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442601\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047687\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179291\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F179278\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047697\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F179304\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047696\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179345\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179297\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179281\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299453\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179286\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179288\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F179299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047692\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179280\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F179296\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5164759\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038653\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13355|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hyaluronidase-drug-information\" class=\"drug drug_general\">Hyaluronidase: Drug information</a></li><li><a href=\"topic.htm?path=hyaluronidase-patient-drug-information\" class=\"drug drug_patient\">Hyaluronidase: Patient drug information</a></li></ul></div></div>","javascript":null}